Evidence map›Paper›PMID 36206229›Full record

ArticlePloS one2022

Expression profile of serum LncRNA THRIL and MiR-125b in inflammatory bowel disease.

Azza Elamir, Olfat Shaker, Marwa Kamal, Abeer Khalefa, Mostafa Abdelwahed, Fadwa Abd El Reheem, Tarek Ahmed, Essam Hassan, Shymaa Ayoub

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Azza ElamirMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Olfat ShakerMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Marwa KamalDepartment of Clinical Pharmacy, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.
Abeer KhalefaDepartment of Physiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Mostafa AbdelwahedDepartment of Physiology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Fadwa Abd El ReheemDepartment of Clinical and Chemical Pathology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Tarek AhmedDepartment of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Essam HassanDepartment of Tropical Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Shymaa AyoubMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.ORCID 0000-0003-1688-3891
Fayoum University · EGCairo University · EGZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. We aimed to investigate, for the first time, the expression profile of serum level of LncRNA THRIL and MiR-125b in IBD patients and their relations with patient's clinical and biochemical investigations.

methodsOur study included 210 subjects divided into 70 healthy subjects considered as control group (male and female), 70 patients with ulcerative colitis (UC), and 70 patients with Crohn's disease (CD). Blood samples were obtained from all subjects. Expression of LncRNA THRIL and MiR-125b in serum was detected by Quantitative real time PCR (qRT-PCR).

resultsOur results showed a significant increase in the fold change of LncRNA THRIL in UC patients (Median = 11.11, IQR; 10.21-12.45, P<0.001) and CD patients (Median = 5.87, IQR; 4.57-7.88, P<0.001) compared to controls. Meanwhile there was a significant decrease in the fold change of MiR-125b in UC patients (Median = 0.36, IQR; 0.19-0.61, P<0.001) and CD patients (Median = 0.69, IQR; 0.3-0.83, P<0.001) compared to controls. Furthermore, there was a negative significant correlation between LncRNA THRIL and MiR-125b in UC patients (r = -0.28, P = 0.016) and in CD patients (r = -0.772, P<0.001). ROC curve analysis was done showing the diagnostic value of these markers as predictors in differentiating between cases of UC, CD, and control.

conclusionSerum LncRNA THRIL and MiR-125b could be used as potential biomarkers for diagnosis and prognosis of ulcerative colitis and Crohn's disease.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesMicroRNAsRNA, Long NoncodingBiomarkersFemaleHumansMaleBiomarkersMicroRNAsRNA, Long Noncoding

Identifiers

PMID36206229
PMCPMC9543963
OpenAlexW4303453807

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.